Advancing Stem Cell Biology toward Stem Cell Therapeutics

Slides:



Advertisements
Similar presentations
Distinct Self-Renewal and Differentiation Phases in the Niche of Infrequently Dividing Hair Follicle Stem Cells Ying V. Zhang, Janice Cheong, Nichita Ciapurin,
Advertisements

Treating the Developing versus Developed Brain: Translating Preclinical Mouse and Human Studies B.J. Casey, Charles E. Glatt, Francis S. Lee Neuron Volume.
Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair Francesco S. Loffredo, Matthew L. Steinhauser,
Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.
Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells David J. Wong, Helen Liu, Todd W. Ridky, David Cassarino, Eran Segal, Howard.
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.
Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells Keriayn N. Smith, Amar M. Singh, Stephen Dalton Cell Stem Cell Volume 7, Issue.
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities Koen Schepers, Timothy B. Campbell, Emmanuelle Passegué Cell Stem Cell Volume.
Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.
Clinical Research Contribution towards improving Clinical Care
Stem Cells in Wound Healing: The Future of Regenerative Medicine
Kevin G. Chen, Barbara S. Mallon, Ronald D.G. McKay, Pamela G. Robey 
Volume 70, Issue 4, Pages (May 2011)
Volume 70, Issue 4, Pages (May 2011)
Back to 2D Culture for Ground State of Intestinal Stem Cells
Volume 1, Issue 5, Pages (November 2007)
Kevin G. Chen, Barbara S. Mallon, Ronald D.G. McKay, Pamela G. Robey 
Volume 1, Issue 1, Pages (June 2007)
Cell Cycle Rules Pluripotency
Improving Stem Cell Therapeutics with Mechanobiology
Stem cell therapies for liver failure and cirrhosis
A Path to Insulin Independence: “The End of the Beginning”
Antibiotics: A New Hope
Volume 9, Issue 2, Pages (August 2011)
Volume 24, Issue 3, Pages (September 2016)
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
New Japanese Initiatives on Stem Cell Therapies
Public Private Partnerships: A Marriage of Necessity
Volume 20, Issue 6, Pages (June 2017)
Therapeutic Translation of iPSCs for Treating Neurological Disease
Volume 14, Issue 2, Pages (February 2014)
Wing Y. Chang, William L. Stanford  Cell Stem Cell 
Volume 11, Issue 3, Pages (September 2012)
Volume 154, Issue 1, Pages (July 2013)
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Robert Zweigerdt, Ina Gruh, Ulrich Martin  Cell Stem Cell 
Organoid Center Strategies for Accelerating Clinical Translation
Soledad Matus, Danilo B. Medinas, Claudio Hetz  Cell Stem Cell 
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Patients Beware: Commercialized Stem Cell Treatments on the Web
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
Volume 18, Issue 2, Pages (February 2016)
Loukia Yiangou, Alexander D.B. Ross, Kim Jee Goh, Ludovic Vallier 
Puma: Mauling the Intestinal Crypt
Targeting β-catenin in CML: Leukemia Stem Cells Beware!
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Severe Constipation Clinical Gastroenterology and Hepatology
Volume 11, Issue 6, Pages (December 2012)
Lung Cancer: A Wily Genetic Opponent
The Promise and Perils of Stem Cell Therapeutics
Paul J. Wrighton, Laura L. Kiessling  Cell Stem Cell 
Volume 21, Issue 9, Pages (September 2014)
Regulating Autologous Adult Stem Cells: The FDA Steps Up
NO Signals from the Cancer Stem Cell Niche
Clinical Translation of Stem Cell Therapies: A Bridgeable Gap
A Fresh Look at iPS Cells
Anna B. Osipovich, Mark A. Magnuson  Cell Stem Cell 
Cardiac Stem Cell Therapy and the Promise of Heart Regeneration
Preoperative Smoking Cessation: The Role of the Primary Care Provider
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Overcoming Challenges Facing Advanced Therapies in the EU Market
Regulating Autologous Adult Stem Cells: The FDA Steps Up
Volume 11, Issue 6, Pages (December 2012)
Devyn M. Smith, Emily J. Culme-Seymour, Chris Mason  Cell Stem Cell 
Cellular Alchemy and the Golden Age of Reprogramming
Memoirs of a Reincarnated T Cell
Modeling Brain Disease in a Dish: Really?
Knocking the Wnt out of the Sails of Leukemia Stem Cell Development
Presentation transcript:

Advancing Stem Cell Biology toward Stem Cell Therapeutics David Scadden, Alok Srivastava  Cell Stem Cell  Volume 10, Issue 2, Pages 149-150 (February 2012) DOI: 10.1016/j.stem.2012.01.010 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Steps in the Translation of Stem Cell Research to Cell Therapeutics: From Bench to Bedside Translation begins with basic research to identify, isolate, culture, characterize, and differentiate the stem cell population of interest. Next, preclinical studies are needed to test strategies to reach appropriate therapies. This occurs in multiple steps: (1) the testing of function, using appropriate animal models if they exist, to evaluate the infusion, homing, and regenerative abilities of the cells of interest; (2) the determination (where possible) of the mechanism or mode of action underlying the treatment; and (3) the development of methods for the large-scale clinical-grade expansion and storage of these cells for clinical trials. Once rigorous preclinical testing has suggested an expected efficacy and often a mode of action or mechanism, the third step involves phased clinical trials that evaluate the safety, the route of administration in the appropriate patient population, and the efficacy of the treatment as per current Good Clinical Practice (GCP) guidelines. If the treatment is judged to be safe and effective and to offer advantages over existing treatments, it may be approved for and adopted as a standard of care. In this process, questions may arise that necessitate further preclinical studies. It must also be recognized that, in certain circumstances, very few patients (usually fewer than five) may be treated with innovative cell therapies outside of the classical clinical trial paradigm (“medical innovation”). If such treatments show encouraging results, they should be evaluated through a clinical trial process before becoming the standard of care. Innovation with advanced technologies can occur at all steps along the translation pathway. Cell Stem Cell 2012 10, 149-150DOI: (10.1016/j.stem.2012.01.010) Copyright © 2012 Elsevier Inc. Terms and Conditions